Bilateral temporal-interference stimulation can improve working-memory capacity in healthy adults by eleven to fourteen percent, and two startups—Cerebrus Sound and FocusLoop—plan to lease the hardware to knowledge-work employers starting in the first quarter of 2027. The FDA has established a medical template for at-home neurostimulation. State legislatures in California and Illinois are drafting restrictions on neural-data collection in workplaces. Yet through mid-September 2026, no labor union, worker advocate, or private attorney has filed a grievance, an unfair labor practice charge, or a civil complaint specifically challenging employer-mandated or employer-incentivized cognitive enhancement.
I searched the NLRB's electronic filing system, PACER federal court dockets, and the press archives of the AFL-CIO, SEIU, and Teamsters. The result across all three channels is identical: nothing. Not a withdrawn charge, not an administrative inquiry, not a position paper demanding bargaining over neural-stimulation benefits. The legal commentary is active—employment-law blogs and academic labor forums are sketching theories that mandatory "attention leasing" could violate the NLRA's prohibition on surveillance and interference with protected concerted activity, and that performance dashboards tied to neural stimulation records might breach state privacy statutes—but these frameworks remain speculative, with no litigation attached.
This silence is not complacency. It is structural. California's Assembly Bill 1883, which passed the Assembly in May and is now before the Senate, would bar employers from using AI-powered surveillance tools to collect neural data or infer emotional states, with penalties of up to five hundred dollars per violation. Illinois has pending legislation that would amend its Biometric Information Privacy Act to include neural data under written-consent rules. Senator Chuck Schumer has asked the Federal Trade Commission to study neural data collection. These are legislative and regulatory responses, not labor actions. They address the privacy of the data, not the labor status of the enhanced worker.
The ambiguity matters because it determines who has standing to challenge what. If cognitive enhancement is classified as a medical benefit, the fight belongs to benefits lawyers and ERISA courts. If it is surveillance, the NLRB and state labor boards have jurisdiction. Until a company actually deploys a program and a worker actually objects, the category remains unsettled, and without a settled category there is no clear defendant, no clear forum, and no clear remedy.
The synchronized delay is the point. The FDA waits for a regulatory filing; unions wait for a mandatory deployment; startups wait for regulatory clarity. In that interval, attention leasing is being normalized as productivity infrastructure before either safety or labor frameworks have been tested against a live case. The first grievance, when it comes, will not be about a novel technology. It will be about a technology that has already become routine.
Sources
– NLRB Case Search (efile.nlrb.gov)
– PACER Federal Court Docket Search
– AFL-CIO Press Releases
– SEIU Press Releases
– Teamsters Newsroom
– Bloomberg Law, "As Neurotech Goes Mainstream, States Move to Regulate It at Work" (2026-08-19)
– Los Angeles Times, "California Bill Would Bar AI Tools From Reading Workers' Brain Data" (2026-08-19)
– California State Legislature, AB 1883 Workplace Surveillance Tools (2025-2026 Regular Session)